24/12/2021 |
Second Supply Agreement for Anagenics’ FGF5 Inhibitors |
15/12/2021 |
Change of Company Name |
09/12/2021 |
Annual General Meeting – CEO Presentation |
09/12/2021 |
Release of Shares from Voluntary Escrow |
09/12/2021 |
Results of Annual General Meeting |
10/11/2021 |
Cellmid receives R&D tax credit |
09/11/2021 |
Letter to Shareholders – Notice of Annual General Meeting |
09/11/2021 |
Notice of Annual General Meeting – Proxy Form |
09/11/2021 |
Proposed issue of securities – CDY |
08/11/2021 |
Final Director’s Interest Notice – Eck-Thompson |
08/11/2021 |
Initial Director’s Interest Notice – Christopher |
08/11/2021 |
Jobkeeper Payments Notification |
05/11/2021 |
Becoming a substantial holder from HNG |
02/11/2021 |
Application for quotation of securities – CDY |
02/11/2021 |
Appointment of Non-Executive Director |
02/11/2021 |
BLC Cosmetics Acquisition Completed |
02/11/2021 |
Cleansing Notice |
22/10/2021 |
General Meeting Presentation |
19/10/2021 |
Appendix 4C and Quarterly Activity Report |
13/10/2021 |
Notification of cessation of securities – CDY |
26/09/2021 |
Investor Webinar |
24/09/2021 |
Change of Director’s Interest Notice – Halasz |
22/09/2021 |
Letter to Shareholders – Notice of General Meeting |
22/09/2021 |
Notice of General Meeting/Proxy Form |
20/09/2021 |
Annual Report to shareholders |
20/09/2021 |
Appendix 4G and Corporate Governance Statement |
16/09/2021 |
BLC Cosmetics to merge with Cellmid |
16/09/2021 |
Cellmid to Acquire BLC Cosmetics Pty Ltd |
16/09/2021 |
Proposed issue of securities – CDY |
19/08/2021 |
Appendix 4E and FY21 Financial Report |
20/07/2021 |
Appendix 4C and Quarterly Activity Report |
09/07/2021 |
Notification of cessation of securities – CDY |
02/07/2021 |
MarketLit Investor Conference Presentation |
17/06/2021 |
Cellmid Reports Record QVC Sales |
10/06/2021 |
FGF5 Inhibitors Supply Agreement – Additional Information |
10/06/2021 |
Release of Shares from Voluntary Escrow |
08/06/2021 |
Supply Agreement for Cellmid’s FGF5 Inhibitors |
02/05/2021 |
Investor Briefing and Presentation |
30/04/2021 |
Chinese Import Permits Received |
29/04/2021 |
Agreement Signed for Sale of Lyramid Limited |
29/04/2021 |
Investor Briefing |
23/04/2021 |
Appendix 4C and Quarterly Activity Report |
01/04/2021 |
Appendix 2A |
01/04/2021 |
CDYOA Top20 and Distribution List |
01/04/2021 |
Change of Director’s Interest Notice – Cross |
01/04/2021 |
Change of Director’s Interest Notice – Eck |
01/04/2021 |
Change of Director’s Interest Notice – Gordon |
01/04/2021 |
Change of Director’s Interest Notice – Halasz |
31/03/2021 |
Proposed issue of Securities – CDY |
31/03/2021 |
Rights Issue Closed with Strong Demand |
31/03/2021 |
Supplementary Prospectus |
25/03/2021 |
Cellmid receives R&D tax credit |
12/03/2021 |
Dispatch of Rights Issue Documentation Completed |
10/03/2021 |
Investor Presentation |
09/03/2021 |
Commencement of the Trading of Rights on the ASX |
08/03/2021 |
Appendix 3B |
08/03/2021 |
Pause in Trading |
08/03/2021 |
Rights Issue |
08/03/2021 |
Rights Issue Prospectus |
25/01/2021 |
Appendix 4C and Quarterly Activity Report |
24/01/2021 |
Cellmid Receives First Order From Chinese Distributor |
15/01/2021 |
Appendix 2A |
04/01/2021 |
Final Director’s Interest Notice – King |